hemodialysis
Conditions
Interventions
Experimental Group 1:HD 3 times/2 weeks, HDF 1 time/2 weeks, HD+pHA130 1 time/week
Experimental Group 2:HD 5 times/2 weeks, HD+pHA130 1 time/2 weeks
control group:HD 5 times/2 weeks, HDF 1 time/2 weeks
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Patients with end-stage renal disease undergoing maintenance hemodialysis treatment; (2) Age between 18 and 75 years old, no gender limitation; (3) Regular hemodialysis, 3 times per week, 4 hours per session, treatment duration = 3 months; (4) Using autologous arteriovenous fistula or transplanted intravascular fistula as vascular acces and have a blood flow = 200ml/min. (5) Willing and able to receive treatment according to the requirements of the program, and have signed the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Patients treated with a combination of hemodialysis and peritoneal dialysis; (2) Patients who have undergone hemoperfusion therapy for more than one month in the past three months. (3) Patients who are known to have allergic reactions, contraindications, or intolerance to dialyzer materials; (4) Patients with acute severe infection, severe cardiopulmonary insufficiency, severe cerebrovascular disease, severe bleeding tendency or active bleeding, malignant tumors, etc.; (5) Patients with a platelet count less than 60×109/L; (6) Patients with a life expectancy of less than 2 years; (7) Patients currently or recently (within 30 days) participating in other clinical trials; (8) Patients who refuse to sign the informed consent form; (9) Other situations where researchers deem it inappropriate to participate in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clearance rate of protein-bound toxin of indoxyl sulfate (IS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Clearance rate of YKL-40;Clearance rate of PCS;Decline rate of ß2-microglobulin;hemodialysis-related complications;routine blood test;blood chemistry;serum lipid parameter;blood pressure;quality of life;Pruritus;Pittsburgh sleep quality index,PSQI; | — |
Countries
China
Contacts
Public ContactShaobin Yu
West China Hospital, Sichuan University
Outcome results
None listed